Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - PHARMACEUTICAL HOLDRS TRUST | ss102005_8k-pharm.htm |
|
PROSPECTUS SUPPLEMENT
|
EXHIBIT 99.1
|
|
(To Prospectus dated April 15, 2010)
|
REGISTRATION NO. 333-92161
|
1,000,000,000 Depositary Receipts
Pharmaceutical HOLDRS (SM) Trust
This prospectus supplement supplements information contained in the prospectus dated April 15, 2010 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS Trust.
The share amounts specified in the table in the “Highlights of Pharmaceutical HOLDRS” section of the base prospectus shall be replaced with the following:
|
Name of Company1
|
Ticker
|
Share
Amounts
|
Primary
Trading
Market
|
||||
|
Abbott Laboratories
|
ABT
|
14.0000 |
NYSE
|
||||
|
Allergan, Inc.
|
AGN
|
2.0000 |
NYSE
|
||||
|
Bristol-Myers Squibb Company
|
BMY
|
18.0000 |
NYSE
|
||||
|
Eli Lilly & Company
|
LLY
|
10.0000 |
NYSE
|
||||
|
Forest Laboratories, Inc.
|
FRX
|
4.0000 |
NYSE
|
||||
|
Hospira, Inc.
|
HSP
|
1.4000 |
NYSE
|
||||
|
Johnson & Johnson
|
JNJ
|
26.0000 |
NYSE
|
||||
|
King Pharmaceuticals, Inc.
|
KG
|
4.2500 |
NYSE
|
||||
|
Medco Health Solutions, Inc.
|
MHS
|
5.3064 |
NYSE
|
||||
|
Merck & Co., Inc.
|
MRK
|
30.0738 |
NYSE
|
||||
|
Mylan Laboratories, Inc.
|
MYL
|
2.2500 |
NASDAQ GS
|
||||
|
Pfizer Inc.
|
PFE
|
69.8200 |
NYSE
|
||||
|
Valeant Pharmaceuticals International, Inc.
|
VRX
|
5.7809 |
NYSE
|
||||
|
Watson Pharmaceuticals, Inc.
|
WPI
|
1.0000 |
NYSE
|
||||
|
Zimmer Holdings Inc.
|
ZMH
|
1.8000 |
NYSE
|
The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.
The date of this prospectus supplement is October 4, 2010.
1 On September 28, 2010, the merger of Valeant Pharmaceuticals International and Biovail Corporation became effective. Also, effective September 28, 2010, Biovail Corporation changed its name to (New) Valeant Pharmaceuticals International, Inc. As a result, (Old) Valeant Pharmaceuticals International, Inc. will no longer be an underlying constituent of the Pharmaceutical HOLDRS Trust. In connection with the merger, (Old) Valeant Pharmaceuticals International, Inc. shareholders will receive 1.7809 shares of (New) Valeant Pharmaceuticals International, Inc. The Bank of New York Mellon will receive 1.7809 shares of (New) Valeant Pharmaceuticals International, Inc. per 100 share round lot of Pharmaceutical HOLDRS. As a result, once the allocation has been completed by The Depository Trust Company, creations of Pharmaceutical HOLDRS will require a deposit of 5.7809 shares of (New) Valeant Pharmaceuticals International, Inc. per 100 share round lot of Pharmaceutical HOLDRS.